Phase 2 N=11 Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis
Fibrillary Glomerulonephritis
Primary: Change in 24 Hour Creatinine Clearance — 41.0 mL/min/SA — p=0.072
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=15 Permeability Factor in Focal Segmental Glomerulosclerosis
Focal Segmental Glomerulosclerosis
Primary: Reduction in Proteinuria in Recurrent FSGS Following Renal Transplant With Plasma Exchange and Cyclophosphamide. — 0; 0; 0.5; 0.25 proportion of participants with…
Phase 4 N=16 Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH
Kidney Diseases
Primary: 24 Hour Proteinuria — 3.6; 3.8; 2.2; 3.0 g/day
Phase 4 N=63 Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria
Idiopathic Focal Segmental Glomerulosclerosis
Primary: Number of Participants With Adverse Events — 0; 11; 60 Participants
Phase 2 N=21 Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)
Fibrosis · Focal Glomerulosclerosis · Kidney Failure
Primary: Decrease in GFR During Treatment Period — -0.45 ml/min/1.73 m2 — p=<0.01
Phase 2 N=67 A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis
Kidney Disease, Chronic
Primary: Achievement of at Least 25% Reduction in 24-hour Urine Protein Creatinine Ratio (UPCR) Relative to Baseline at Week 12 — 48.9; 16.0; 38.5; 11.4 Predicted percentage of…
Phase 2 N=23 Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial
Focal Segmental Glomerulosclerosis
Primary: Number of Participants With a Reduction in Proteinuria at 6 Months by > 50% of the Value at Screening AND Stable GFR Defined as Greater Than 75 ml/Min/1.73m2 in Those…
Phase 2 N=14 A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy
Glomerulonephritis, Membranous
Primary: Change From Baseline in Proteinuria Levels at Week 28 — 0.7552 Ratio
Phase 2 N=21 Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
IgA Nephropathy · Lupus Nephritis · Membranous Nephropathy
Primary: Part A: Change From Baseline in Proteinuria at Week 48 — -0.1364; 0.3560; 0.3430; -2.0347 ratio
Phase 2 N=12 Daratumumab in Treatment of PGNMID and C3 GN
Membranoproliferative Glomerulonephritis
Primary: Number of Treatment-Emergent Adverse Events — 5 Serious Adverse Events
N/A N=7 Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome
Focal Segmental Glomerulosclerosis · Steroid Resistant Nephrotic Syndrome
Primary: Focal Segmental Glomerulosclerosis Permeability Factor (FSPF) — 0.69; 0.35 Palb — p=0.009
Phase 3 N=371 Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
Focal Segmental Glomerulosclerosis
Primary: Slope of Estimated Glomerular Filtration Rate (eGFR) — -5.4; -5.7 milliliters/minute/1.73square meter/year — p=0.7491
Phase 2 N=7 Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
FSGS · MCD · Focal Segmental Glomerulosclerosis
Primary: Change in Urine MCP1/Cr Levels — 5.57; 2.89 ng/mg
Phase 3 N=194 Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients
Renal Interstitial Fibrosis
Primary: Number of Participants With Progression of Renal Graft Fibrosis (Primary Comparison - ITT Population — 26; 31; 12; 16 Participants
Phase 4 N=40 Mycophenolate Mofetil and Tacrolimus Versus Tacrolimus for the Treatment of Idiopathic Membranous Glomerulonephritis
Glomerulonephritis, Membranous
Primary: Number of Patient Who Gained Remission From the Nephrotic Syndrome — 8; 8 Participants — p=0.7
Phase 4 N=34 Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy
IgA Nephropathy
Primary: Change in Proteinuria at 12 Months — 3; 3; 1; 2 participants
Phase 3 N=39 Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy
Glomerulonephritis, Membranous
Primary: Percentage of Complete Remission — 4; 3 Participants
Phase 2 N=54 Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy
Immunoglobulin A (IgA) Nephropathy
Primary: Part 1: Relative Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) in 24-hour Urine at Month 9 — -24.7; -16.5; -30.6; -38.5 gram per gram (g/g) — p=0.6837
Phase 3 N=128 Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis
Familial Amyloid Polyneuropathy
Primary: Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 18 — 45.3; 29.5 percentage of participants
Phase 2 N=20 IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3
Small Fiber Neuropathy · Idiopathic Peripheral Neuropathy
Primary: The Change in Nerve Fiber Density Between Visits 1 and 8. — 0.5; 0.6 fibers/mm
Phase 2 N=12 Podocyte Retinoids
Collapsing Glomerulopathy · Glomerulosclerosis, Focal Segmental
Primary: Change in Proteinuria at Week 24 From Baseline — 8.42; 7.67 g/g
N/A N=18 FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease
Secondary Hyperparathyroidism
Primary: Change in FGF-23 Level — 16; 41 percentage change from baseline
Phase 2 N=17 A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Glomerulosclerosis, Focal Segmental
Primary: Number of Participants Meeting the Definition of Responder for Reduction in Proteinuria at the Indicated Time Points — 0; 1; 0; 0 Participants
N/A N=43 Fibroblast Growth Factor-23 (FGF23) Reduction in Predialysis Chronic Kidney Disease (CKD)
Kidney Disease
Primary: Percentage Changes in Fibroblast Growth Factor-23 (FGF-23) Levels — -0.35; 0.25; 0.00; -0.02 percentage of change from baseline
Phase 2 N=9 Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)
Lupus Membranous Nephropathy
Primary: Percent Change in Urine Protein From Baseline (Day 1) to Week 16 — -2.8; -51.2 percent change
Phase 2 N=109 Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Focal Segmental Glomerulosclerosis
Primary: Percent Change in Urine Protein/Creatinine (Up/C) — -44.8; -18.5; -47.4; -33.1 percent change
Phase 3 N=8 Steroid Treatment for Kidney Disease
Nephrosis · Focal Lipoid Glomerulosclerosis
Primary: Remission Status of Patients After Intermittent Oral Dexamethasone Administered Over 48 Weeks — 1; 1; 2; 1 participants — p=0.9074
N/A N=31 Study of Dietary Additive Phosphorus on Proteinuria and Fibroblast Growth Factor-23
Albuminuria
Primary: 24-hour Urine Albumin Excretion — 86.2; 76.4 mg/day — p=0.05
Phase 2 N=76 Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy
IGA Nephropathy
Primary: Mean Change of Proteinuria as Measured by Spot Urine Protein/Creatinine Ratio (sPCR) at Week 24 — -157.5; -577.2; -177.4 mg/g — p=0.97
Phase 2 N=9 A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS
Primary Focal Segmental Glomerulosclerosis
Primary: Changes in Proteinuria (With Stable Renal Function) — 7.6; 7.27 g/day — p=0.49